about
The Effects of a Synbiotic Addition on Eradication Therapy of Helicobacter Pylori Infection in ChildrenStudy Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental DrugQuality of Life Validation in LaryngitisComparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus OmeprazoleReflux Esophagitis Phase III Study (Maintenance Treatment)Reflux Esophagitis Phase III Study (Initial Treatment)Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in GastroparesisPharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and Mental RetardationA Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female VolunteersEvaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced MalignanciesEffect of a Proton Pump Inhibitor on Gleevec® in Healthy VolunteersA Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy SubjectsHigh Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer BleedingStudy to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.Tongue Exercises and Reflux Therapy for Upper Airway Resistance SyndromeRole of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and OmeprazoleDoes Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori EradicationAn Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple SclerosisProton Pump Inhibitors and Dysbiosis in CirrhosisEffect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy AdultsLactobacillus Reuteri ProGastria in Helicobacter Pylori-infected Adult Subjects on Proton Pump InhibitorsFrom the Biomedical to the Biopsychosocial Model, From Theory to PracticeA Drug-Drug Interaction Study of Omeprazole and PA21Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal BleedingEffect of the CYP2C19 Polymorphism in Helicobacter Pylori EradicationA Study of Perpetrator Drug Interactions of Enasidenib in AML PatientsDrug Interaction Study of CT1812 in Healthy VolunteersPharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other DrugsIndomethacin for Refractory Chronic CoughAntibiotic Therapy and Antacids in Patients With Malt Lymphoma of the StomachInfluence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole.A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)Efficacy and Safety Evaluation of Neobianacid® in GERD and EPSAssess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs as a Means of Predicting Drug-drug InteractionsOpen-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female SubjectsDevelopment of Minidose Inje Cocktail Method for Simultaneous Evaluating Five Cytochrome P450 Isoforms in Human
P4844
Q61908824-900FE50A-02B0-44C1-AF60-C18DFBA61CC2Q61914486-83420593-85B0-4353-91C9-2140724CF095Q61914840-F4E15603-70D1-4197-A616-66A13045763EQ61914852-34358C68-BB4C-4397-BD20-54BB9676178CQ61915543-F8223884-286C-42E8-9179-781D0EF48846Q61915559-9212D987-818E-40D3-8F6A-53F9141FA5DDQ61917874-E2721E94-601B-4337-AF82-EF47BBFA8348Q61921421-BEA082F1-EE39-4C23-BAFF-12BB89B68491Q61921433-2D1A8BF6-57C3-40FE-BA11-C8C09096F891Q61921962-FCA44D5B-4479-4E63-BBF4-DF673F26EFF6Q61924483-DAF54B00-7DFD-4021-B1AC-CB9B9AF57F78Q61924910-8D316B55-1426-458A-93AF-65D2CCFA52F1Q61932640-63DA064F-FAB8-4C5B-8BBA-6F829E481B5CQ61933946-1B62886F-0ED4-43AA-89F8-6D1C9DF222E9Q61934499-421BCB50-5DC9-401A-87F3-0B3BEBE01C7EQ61936794-D94704B5-C6A7-40CC-B0E9-EC6E09F98542Q61936851-41833E89-18CE-4848-BC8E-827169641A7FQ61938064-27E8DEB4-4554-4C18-8CB6-CA784C605677Q61955637-053E5ABB-18C2-41DA-BD84-584DB4853F4BQ61956615-69664F7E-D5E1-4897-BE44-54985E5444A1Q61956809-49FC19F8-FFFA-44C5-B8C9-D8B82BAD0265Q61957094-6726065D-A4B8-4945-8DE5-FEB7D6EAB240Q61965826-B82545DF-B93F-4668-83EF-00FF54FB9FA7Q61965912-E5FFE8B1-1F7A-4021-B897-9827307485B1Q61966032-71AB6C9D-FB5F-4680-9BE9-BE330E8F73DFQ61966069-E4A39532-24BD-46E3-BBAD-CE1EA8F3A064Q61966984-84EE7C45-ACE7-4F00-BFA6-176198868A44Q61981384-D9741512-C1DE-4332-AE02-E2881A75883DQ62025413-039FEE83-2A2E-439A-AC5B-FFE314D329DEQ62039941-6F53B5E6-8C76-4281-81AB-44E2A9C23F86Q62040775-24271121-49A6-4446-AA49-CFF6693ED30AQ62042281-4FE6D1CF-8481-4A55-9594-BDFEECF30278Q62062245-E59F15EA-D638-4981-9CD6-A89C357765FDQ62110770-C4C5BFE7-F974-4A83-B151-ED627248124DQ62819236-D98285E7-5449-432D-97A1-AE36E6141F91Q62823249-E0A98451-9DB8-484A-9E9E-08DA6381745CQ63010719-565CC1E0-20ED-45CD-9CA3-7F5FC7B7FF61Q63011638-FFE5414F-F482-412B-BE9D-E135B21DBEB4Q63062692-7EA91F5D-551C-4A03-B5DC-504B683A86DEQ63316847-A74179C5-D82A-4815-B2C8-5F05EFBB20C0
P4844
description
combination drug
@en
lek złożony
@pl
name
Omeprazole / Sodium Bicarbonate
@en
omeprazol/wodorowęglan sodu
@pl
type
label
Omeprazole / Sodium Bicarbonate
@en
omeprazol/wodorowęglan sodu
@pl
prefLabel
Omeprazole / Sodium Bicarbonate
@en
omeprazol/wodorowęglan sodu
@pl